https://www.globenewswire.com/news-release/2019/07/08/1879407/0/en/Prevail-Therapeutics-Receives-U-S-FDA-Fast-Track-Designation-for-PR001-for-the-Treatment-of-Parkinson-s-Disease-Patients-with-a-GBA1-Mutation.html
Prevail Therapeutics Receives U.S. FDA Fast Track Designation for PR001 for the Treatment of Parkinson’s Disease Patients with a GBA1 Mutation
Company Plans to Initiate Phase 1/2 Clinical Trial in the Second Half of 2019
